| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human NGEF recombinant protein (Position: E82-Q627) was used as the immunogen for the NGEF antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
NGEF Antibody / Ephexin 1 is an antibody targeting NGEF. Host: Rabbit. Polyclonal. Format: Lyophilized. Applications: ELISA, FACS, WB.
Key elements and design rationale
- Target: NGEF.
- Immunogen: E.coli-derived human NGEF recombinant protein (Position: E82-Q627) was used as the immunogen for the NGEF antibody..
- Species reactivity: Human.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
NGEF antibody detects Ephexin 1, encoded by the NGEF gene. Ephexin 1 is a guanine nucleotide exchange factor that regulates Rho family GTPases, controlling cytoskeletal dynamics, neuronal signaling, and axon guidance.
Common research applications
- WB: relative abundance and band pattern assessment using appropriate controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
